IL-2: IL-2RA Inhibitor Screening Colorimetric Assay Kit
The IL-2: IL-2 Receptor Alpha (IL-2RA) Inhibitor Screening Colorimetric Assay Kit is designed for the screening and profiling of inhibitors or neutralizing antibodies blocking the interaction between human IL-2 and its receptor IL-2RA.
The assay requires only a few steps. First, IL-2RA is coated on a 96-well plate overnight. After blocking, the receptor is pre-incubated with the test inhibitor or neutralizing antibody. Upon subsequent incubation with Biotin-IL-2, the plate is treated with Streptavidin-HRP followed by addition of a colorimetric HRP substrate to produce color, which can be quenched and measured using a UV/Vis microplate reader.
Need us to run inhibitor screens or profile your compounds against IL-2: IL-2RA? Check out our Immunotherapy Biochemical Screening Services.
- PBS (Phosphate buffered saline)
- 1N HCl (aqueous)
- Rotating or rocker platform
- UV/Vis spectrophotometer microplate reader capable of reading absorbance at 450 nm
Catalog # | Name | Amount | Storage |
101203 | IL-2RA, Avi-His Tag* | 2 x 10 µg | -80°C |
101381 | IL-2, Fc-Avi-Tag, Biotin-Labeled* | 2 x 5 µg | -80°C |
79311 | 3x Immuno Buffer 1 | 50 ml | -20°C |
79728 | Blocking Buffer 2 | 50 ml | +4°C |
79742 | Streptavidin-HRP | 10 µl | +4°C |
79651 | Colorimetric HRP substrate | 10 ml | +4°C |
79964 | Transparent 96-well microplate | 1 | Room Temp |
*The initial concentration of both IL-2RA and IL-2 is lot-specific and will be indicated on the tube containing the protein.
Interleukin-2 (IL-2) is a cytokine secreted by activated T lymphocytes to stimulate the proliferation of both B and T cells. IL-2 is involved in the extreme inflammation response termed “cytokine storm” observed following viral infection in susceptible patients or following adaptive cell therapy. Thus, it is considered a therapeutic target for the treatment of severe COVID-19.
IL-2 acts by binding to a membrane heterotrimeric receptor consisting of IL-2 receptor alpha (IL2RA, also known as CD25) and beta (IL2RB) chains, which together with the common gamma chain (IL2RG) form a high-affinity receptor, whereas IL-2RA homodimers form a low-affinity receptor. Polymorphisms in the genes coding for IL2RA and IL2RB may be associated with risk of lung cancer.